Vantaggi
*Robust pre-clinical discovery programs (quality and number) *Talent below Director level (although eroding with high turnover rates) *Immune Oncology portfolio *Great clinical teams *Strong core groups (although quite understaffed)
Svantaggi
*Dysfunctional leadership at the very top (high nepotism and cronyism practices) *Some of the lowest work morale in the industry (driving high employee turnover rates) *Inability of leadership to focus and execute against portfolio (high micromanagement practices) *Promotions based on popularity contest instead of accomplishments and qualifications *Failure of leadership to manage expectations and deliverables from core clinical support groups (e.g., PK, Tox, Ops, etc) versus translational medicine (e.g., Ph1-2 early development clinical sciences, iMED and translational medicine) *Inability of leadership to provide vision and definitive goals